secwatch.observer — SEC 8-K summary
======================================

Issuer:     TALPHERA, INC. (TLPH)
CIK:        0001427925
Form:       8-K
Filed at:   2025-03-31T23:59:59+00:00
Accession:  0001437749-25-010190
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Talphera reports Q4 2024 net loss $1.9M; FDA cuts NEPHRO study size to 70 patients
--------------------------------------------------------------------------------

- FDA agreed to reduce NEPHRO CRRT study from 166 to 70 patients; study completion targeted by end of 2025.
- Cash and investments of $8.9M at Dec 31, 2024; additional $14.8M private placement financing announced.
- Q4 2024 net loss from continuing operations $1.9M ($0.07 per share) vs $4.5M ($0.25) in Q4 2023.
- Combined R&D and SG&A expenses decreased to $3.0M in Q4 2024 from $4.6M in Q4 2023.
- 2025 cash operating expense guidance of $18M-$19M, includes costs to complete NEPHRO study.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1427925/000143774925010190/0001437749-25-010190-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1427925/000143774925010190/acrx20250330_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-010190

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer